Candidemia in Colombia

Biomédica

View Publication Info
 
 
Field Value
 
Title Candidemia in Colombia
Candidemia en Colombia
 
Creator Cortés, Jorge Alberto
Ruiz, José Franklin
Melgarejo-Moreno, Lizeth Natalia
Lemos, Elkin V.
 
Subject Candidiasis
candidemia
intensive care units
mycoses
invasive fungal infections
candidiasis, invasive
Colombia
candidiasis
candidemia
unidad de cuidados intensivos
micosis
infecciones fúngicas invasivas
candidiasis invasiva
Colombia
 
Description In Colombia, especially in intensive care units, candidemia is a frequent cause of infection, accounting for 88% of fungal infections in hospitalized patients, with mortality ranging from 36% to 78%. Its incidence in Colombia is higher than that reported in developed countries and even higher than in other Latin American countries. First, the patient’s risk factors should be considered, and then clinical characteristics should be assessed. Finally, microbiological studies are recommended and if the evidence supports its use, molecular testing.In general, American, Latin American, and European guides place the echinocandins as the first-line treatment for candidemia and differ in the use of fluconazole based on evidence, disease severity, previous exposure to azoles, and prevalence of Candida non-albicans. Taking into account the high incidence of this disease in our setting, it should be looked for in patients with risk factors to start a prompt empirical anti-fungal treatment.
En Colombia, especialmente en las unidades de cuidados intensivos, la candidemia es una causa frecuente de infección del torrente sanguíneo y representa el 88 % de las infecciones fúngicas en pacientes hospitalizados, con una mortalidad entre 36 y 78 %. Su incidencia en Colombia es mayor a la reportada en los países desarrollados e, incluso, en otros países de Latinoamérica. Para su manejo deben considerarse los factores de riesgo del paciente, luego valorar las características clínicas y, finalmente, hacer los estudios microbiológicos y, si es necesario, pruebas moleculares.En general, las guías estadounidenses, latinoamericanas y europeas recomiendan las equinocandinas como el tratamiento de primera línea de la candidemia y difieren en el uso de fluconazol dependiendo de la ‘evidencia’, la gravedad de la enfermedad, la exposición previa a los azoles y la prevalencia de Candida no albicans. Dada su gran incidencia en nuestro país, asociada con una elevada mortalidad, esta infección debe buscarse sistemáticamente en pacientes con factores de riesgo, con el fin de iniciar oportunamente el tratamiento antifúngico.
 
 
Publisher Instituto Nacional de Salud
 
Date 2020-03-01
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
text/xml
 
Identifier https://revistabiomedica.org/index.php/biomedica/article/view/4400
10.7705/biomedica.4400
 
Source Biomedica; Vol. 40 No. 1 (2020); 195-207
Biomédica; Vol. 40 Núm. 1 (2020); 195-207
2590-7379
0120-4157
 
Language spa
 
Relation https://revistabiomedica.org/index.php/biomedica/article/view/4400/4350
https://revistabiomedica.org/index.php/biomedica/article/view/4400/4549
/*ref*/Cortés JA, Reyes P, Gómez CH, Cuervo SI, Rivas P, Casas CA, et al. Clinical and epidemiological characteristics and risk factors for mortality in patients with candidemia in hospitals from Bogotá, Colombia. Braz J Infect Dis. 2014;18:631-7. https://doi.org/10.1016/j.bjid.2014.06.009 2. Nucci M, Thompson-Moya L, Guzmán-Blanco M, Tiraboschi IN, Cortés JA, Echevarría J, et al. Recommendations for the management of candidemia in adults in Latin America. Latin America Invasive Mycosis Network. Rev Iberoam Micol. 2013;30:179-88. https://doi.org/10.1016/j.riam.2013.05.007 3. Zuluaga-Rodríguez A, De Bedout-Gómez C, Agudelo-Restrepo C, Hurtado-Parra H, Arango-Arteaga M, Restrepo-Moreno A, et al. Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellín, Colombia (2001-2007). Rev Iberoam Micol. 2010;27:125-9. https://doi.org/10.1016/j.riam.2010.04.001 4. Cortés JA, Reyes P, Gómez C, Buitrago G, Leal AL y Group G. Fungal bloodstream infections in tertiary care hospitals in Colombia. Rev Iberoam Micol. 2011;28:74-8. https://doi.org/10.1016/j.riam.2010.12.002 5. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortés J, Zurita J, et al. Epidemiology of candidemia in Latin America: A laboratory-based survey. PLoS ONE. 2013;8:e59373. https://doi.org/10.1371/journal.pone.0059373 6. Berrío I, Maldonado N, De Bedout C, Arango K, Cano LE, Valencia Y, et al. Comparative study of Candida spp. isolates: Identification and echinocandin susceptibility in isolates obtained from blood cultures in 15 hospitals in Medellín, Colombia. J Glob Antimicrob Resist. 2018;13:254-60. https://doi.org/10.1016/j.jgar.2017.11.010 7. Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. Invasive fungal infections in the ICU: How to approach, how to treat. Molecules. 2014;19:1085-119. https://doi.org/10.3390/molecules19011085 8. Scudeller L, Viscoli C, Menichetti F, del Bono V, Cristini F, Tascini C, et al. An Italian consensus for invasive candidiasis management (ITALIC). Infection. 2014;42:263-79. https://doi.org/10.1007/s15010-013-0558-0 9. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis. 2003;3:772-85. https://doi.org/10.1016/S1473-3099(03)00831-4 10. Cortés JA, Corrales IF. Invasive candidiasis: Epidemiology and risk factors in fungal infection. Londres: Intech Open; 2019:33-46. https://doi.org/10.5772/intechopen.81813 11. Ortiz-Ruiz G, Osorio J, Valderrama S, Álvarez D, Elias-Díaz R, Calderón J, et al. Risk factors for candidemia in non-neutropenic critical patients in Colombia. Med Intensiva. 2016;40:139-44. https://doi.org/10.1016/j.medin.2015.08.001 12. De Bedout C, Gómez B. Candida y candidiasis invasora: un reto continuo para su diagnóstico temprano. Infectio. 2010;14:s159-71. https://doi.org/10.1016/S0123-9392(10)70133-8 13. Orozco P, Cortés J, Parra C. Colonización por levaduras en recién nacidos y personal de salud en la unidad de cuidados intensivos neonatales de un hospital universitario en Bogotá, Colombia. Rev Iberoam Micol. 2009;26:108-11 https://doi.org/10.1016/S1130-1406(09)70020-8 14. Díaz-Granados CA, Martínez A, Deaza C, Valderrama S. An outbreak of Candida spp. bloodstream infection in a tertiary care center in Bogotá, Colombia. Braz J Infect Dis. 2008;12:390-4. 15. Asmundsdottir LR, Erlendsdottir H, Haraldsson G, Guo H, Xu J, Gottfredsson M. Molecular epidemiology of candidemia: Evidence of clusters of smoldering nosocomial infections. Clin Infect Dis. 2008;47:e17-24. https://doi.org/10.1086/589298 16. Desai JV, Mitchell AP. Candida albicans biofilm development and its genetic control. Microbiol Spectr. 2015;3(3):MB-0005-2014. https://doi.org/10.1128/microbiolspec.MB-0005-2014 17. Cortés JA, Jaimes JA, Leal AL. Incidencia y prevalencia de candidemia en pacientes críticamente enfermos en Colombia. Rev Chil Infectol. 2013;30:599-604. https://doi.org/10.4067/S0716-10182013000600004 18. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134-40. https://doi.org/10.1093/cid/ciw691 19. Parra-Giraldo CM, Valderrama SL, Cortés-Fraile G, Garzón JR, Ariza BE, Morio F, et al. First report of sporadic cases of Candida auris in Colombia. Int J Infect Dis. 2018;69:63-7. https://doi.org/10.1016/j.ijid.2018.01.034 20. Escandón P, Chow NA, Cáceres DH, Gade L, Berkow EL, Armstrong P, et al. Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance. Clin Infect Dis. 2019;68:15-21. https://doi.org/10.1093/cid/ciy411 21. Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, Martínez HP, Rodríguez GJ, Álvarez-Moreno CA, et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis. 2017;23:162-4. https://doi.org/10.3201/eid2301.161497 22. Motoa G, Muñoz JS, Oñate J, Pallares CJ, Hernández C, Villegas MV. Epidemiology of Candida isolates from intensive care units in Colombia from 2010 to 2013. Rev Iberoam Micol. 2017;34:17-22. https://doi.org/10.1016/j.riam.2016.02.006 23. Thomaz DY, de Almeida JN Jr, Lima GM, Nunes MO, Camargo CH, Grenfell RC, et al. An azole-resistant Candida parapsilosis outbreak: clonal persistence in the intensive care unit of a Brazilian teaching hospital. Front Microbiol. 2018;9:2997. https://doi.org/10.3389/fmicb.2018.02997 24. Cortés JA, Prada G. Protocolo de estudio y manejo de pacientes con candidiasis sistémica en adultos. Infectio. 2012;16:118-22. https://doi.org/10.1016/S0123-9392(12)70037-1 25. Ahmadi A, Ardehali SH, Beigmohammadi MT, Hajiabdolbaghi M, Hashemian SM, Kouchek M, et al. Invasive candidiasis in intensive care unit; consensus statement from an Iranian panel of experts, July 2013. JRSM Open. 2014;5:2042533313517689. https://doi.org/10.1177/2042533313517689 26. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35. https://doi.org/10.1086/596757 27. Díaz J, Urrego J, Moreno J, Huérfano C, Prieto V. Análisis de costo-efectividad de anidulafungina en el tratamiento de la candidiasis invasiva en Colombia. Value Health. 2015;18:A870. https://doi.org/10.1016/j.jval.2015.09.010 28. Kami M, Machida U, Okuzumi K, Matsumura T, Mori Si S, Hori A, et al. Effect of fluconazole prophylaxis on fungal blood cultures: An autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol. 2002;117:40-6. https://doi.org/10.1046/j.1365-2141.2002.03414.x 29. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl.7):19-37. https://doi.org/10.1111/1469-0691.12039 30. León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study. Crit Care Med. 2009;37:1624-33. https://doi.org/10.1097/CCM.0b013e31819daa14 31. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vázquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trial. Clin Infect Dis. 2015;60:892-9. https://doi.org/10.1093/cid/ciu959 32. Berdal JE, Haagensen R, Ranheim T, Bjornholt JV. Nosocomial candidemia; risk factors and prognosis revisited; 11 years experience from a Norwegian secondary hospital. PLoS ONE. 2014;9:e103916. https://doi.org/10.1371/journal.pone.0103916 33. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis. 2006;43:25-31. https://doi.org/10.1086/504810 34. Aguado JM, Ruiz-Camps I, Muñoz P, Mensa J, Almirante B, Vázquez L, et al. Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011. Enferm Infecc Microbiol Clin. 2011;29:345-61. https://doi.org/10.1016/j.eimc.2011.01.008 35. Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, Calandra T, et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect. 2011;17(Suppl.5):1-12. https://doi.org/10.1111/j.1469-0691.2011.03615.x 36. Rodríguez-Adrián LJ, King RT, Tamayo-Derat LG, Miller JW, García CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: Frequency, natural history, and etiology. Medicine (Baltimore). 2003;82:187-202. https://doi.org/10.1097/01.md.0000076008.64510.f1 37. Centers for Disease Control and Prevention. Invasive candidiasis. Fecha de consulta: 31 marzo de 2018. Disponible en: https://www.cdc.gov/fungal/diseases/candidiasis/invasive/index.html 38. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-50. https://doi.org/10.1093/cid/civ933 39. Oñate J, Rivas J, Pallares C, Saavedra C, Martínez E, Coronell W, et al. Colombian consensus on the diagnosis, treatment, and prevention of Candida spp. disease in children and adults. Infectio. 2019;23:271-304. 40. Cortés JA, Russi JA. Equinocandinas. Rev Chil Infectol. 2011;28:529-36. https://doi.org/10.4067/S0716-10182011000700004 41. Marcos-Zambrano LJ, Gómez-Perosanz M, Escribano P, Zaragoza O, Bouza E, Guinea J. Biofilm production and antibiofilm activity of echinocandins and liposomal amphotericin B in echinocandin-resistant yeast species. Antimicrob Agents Chemother. 2016;60:3579-86. https://doi.org/10.1128/AAC.03065-15 42. Marcos-Zambrano LJ, Escribano P, Bouza E, Guinea J. Comparison of the antifungal activity of micafungin and amphotericin B against Candida tropicalis biofilms. J Antimicrob Chemother. 2016;71:2498-501. https://doi.org/10.1093/jac/dkw162 43. Colombo AL, Guimaraes T, Camargo LF, Richtmann R, Queiroz-Telles F, Salles MJ, et al. Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis. 2013;17:283-312.https://doi.org/10.1016/j.bjid.2013.02.001 44. Auzinger G, Playford EG, Graham CN, Knox HN, Weinstein D, Kantecki M, et al. Costeffectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis. BMC Infect Dis. 2015;15:463. https://doi.org/10.1186/s12879-015-1143-1 45. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110-22. https://doi.org/10.1093/cid/cis021 46. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-93. https://doi.org/10.1086/520980 47. Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis. Clin Ther. 2010;32:637-48. https://doi.org/10.1016/j.clinthera.2010.04.005 48. Yan T, Li SL, Wang DX. Comparison between micafungin and caspofungin for the empirical treatment of severe intra-abdominal infections in surgical intensive care patients. Zhonghua Yi Xue Za Zhi. 2016;96:2301-6. https://doi.org/10.3760/cma.j.issn.0376-2491.2016.29.004 49. Botero MC, Puentes-Herrera M, Cortés JA. Formas lipídicas de anfotericina. Rev Chil Infectol. 2014;31:518-27. https://doi.org/10.4067/S0716-10182014000500002 50. Cortés JA, Soto R, Ãlvarez CA, Buitrago G, Camargo RD, Cataño JC, et al. Consenso de uso de antimicrobianos en pacientes críticamente enfermos con falla renal o en riesgo de padecerla. Infectio. 2011;15:49-63. https://doi.org/10.1016/S0123-9392(11)70076-5 51. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472-82. https://doi.org/10.1056/NEJMoa066906 52. Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54:2409-19. https://doi.org/10.1128/AAC.01657-09 53. Maldonado NA, Cano LE, De Bedout C, Arbeláez CA, Roncancio G, Tabares AM, et al. Association of clinical and demographic factors in invasive candidiasis caused by fluconazoleresistant Candida species: A study in 15 hospitals, Medellín, Colombia 2010-2011. Diagn Microbiol Infect Dis. 2014;79:280-6. https://doi.org/10.1016/j.diagmicrobio.2014.02.003 54. Rodríguez-Leguizamón G, Fiori A, Lagrou K, Gaona MA, Ibañéz M, Patarroyo MA, et al. New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogota, Colombia, in ten tertiary care centres: An observational study. BMC Infect Dis. 2015;15:108. https://doi.org/10.1186/s12879-015-0840-0
 
Rights Derechos de autor 2020 Biomédica
https://creativecommons.org/licenses/by/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library